|
Research Area
|
|
Description
|
Cancer,Myelofibrosis, Mantle cell lymphoma |
|
Biological Activity
|
|
Description
|
Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM. |
|
Targets
|
TNF-α |
|
|
|
|
|
|
IC50 |
13 nM [1] |
|
|
|
|
|
|
In Vitro
|
Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4] |
|
In Vivo
|
The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5] |
|
Clinical Trials
|
Lenalidomide has entered in a Phase II clinical trial in the treatment of chronic lymphocytic leukemia. |
|
Features
|
|
|
Combination Therapy
|
|
Description
|
Lenalidomide plus Dexamethasone displays very synergistic results with combination index less than 0.1. [6] At 0.01 μM (in DU145 cells) and 1 μM (in PC3 cells) Lenalidomide reduces the mean IC50 for Docetaxel by 42% and 36% respectively. In PC3 cells, 1 μM Lenalidomide significantly enhances the apoptotic activity of Docetaxel. [7] Lenalidomide reveals synergistic effect in vitro with Bortezomib in co-culture system associating the MCL cell line Jeko-1 to the dendritic-like cells BDCM, by modifying the secretion pattern of these latest. [8] Treated with a combination of Lenalidomide and Docetaxel after the tumors has reached 160?mm2, the tumor growth rate is significantly reduced, and animal survival (as determined by the length of time taken for tumors to reach 15?cm3) is increased from 48 days to 59 days. [9] |
|
Protocol
|
|
Kinase Assay
[1]
|
| Assay for inhibition of TNF synthesis by human PBMCs |
Human PBMCs from normal donors are obtained by Ficoll?Hypaque density centrifugation. Cells (106 cells/mL) are cultured in RPMI supplemented with 10 AB+ serum, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Lenalidomide is dissolved in DMSO at 20 mg/mL; further dilution is done with culture medium. The final DMSO concentration in all assays including the controls is 0.25%. Lenalidomide is added to cells 1 hour prior to the addition of LPS. PBMCs (106 cells/mL) are stimulated with 1 μg/mL of LPS from Salmonella minnesota R595. Cells, in triplicate, are incubated with LPS for 18?20 hours at 37 °C in 5% CO2. Supernatants are then harvested and assayed for cytokine levels. In some experiments, supernatants are kept frozen at ?70 °C until use. Cell viability is assayed by Trypan blue exclusion dye method. The concentration of TNFα in the culture supernatants is determined by ELISA. Lenalidomide is assayed in a minimum of three separate experiments. Percent inhibition is determined as 100 × [1 ? (cytokine(experimental)/cytokine(control))]. |
|
Animal Study
[5]
|
| Animal Models |
Adult male Sprague-Dawley rats bearing HUVECs cells |
| Formulation |
0.5% DMSO |
| Doses |
50 mg/kg and 250 mg/kg |
| Administration |
Administered via i.p. |
|
References |
|
[1] Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.
|
|
[2] Zangari M, et al. Expert Opin Investig Drugs. 2005, 14(11), 1411-1418.
|
|
[3] Lopez-Girona A, et al. Leukemia. 2012.
|
|
[4] Ramsay AG, et al. Blood, 2012, 120(7), 1412-1421.
|
|
[5] Dredge K, et al. Microvasc Res. 2005, 69(1-2), 56-63.
|
|
[6] Henry JY, et al. Prostate. 2012, 72(8), 856-867.
|
|
[7] Ocio EM, et al. Haematologica, 2010, 95(5), 794-803.
|
|
[8] Henry JY, et al. J Clin Oncol, 2010, 28(suppl), Abst e13155.
|
|
[9] Moros A, et al. Canc Res, 2012, 72(8, Suppl 1), Abstr #1942.
|
|